How has been the historical performance of Amerise BioScie?

Answer:The historical performance of Amerise BioScie shows a trend of minimal activity and fluctuating financial metrics over the years, with net sales consistently at zero from March 2020 to March 2025. Other operating income peaked at 9.01 crore in March 2022 but has since declined to 0.19 crore in March 2025. Total operating income followed a similar pattern, dropping from 9.01 crore in March 2022 to 0.19 crore in March 2025. The company reported total expenditure excluding depreciation of 0.18 crore in March 2025, which is significantly lower than the 9.03 crore recorded in March 2022. Operating profit (PBDIT) showed a recovery to 0.01 crore in March 2025 from a loss of 0.34 crore in March 2021, but overall profitability remains weak, with profit after tax at 0.01 crore in March 2025 compared to a profit of 0.55 crore in March 2022. The balance sheet reflects total liabilities of 8.46 crore in March 2025, up from 5.39 crore in March 2024, while total assets also increased to 8.46 crore in March 2025 from 5.39 crore in March 2024. Cash flow from operating activities was positive at 3.00 crore in March 2025, contrasting with previous years where cash flow was non-existent. Breakdown: Amerise BioScie's financial history indicates a lack of revenue generation, with net sales remaining at zero from March 2020 to March 2025. The company experienced a significant drop in other operating income from a high of 9.01 crore in March 2022 to just 0.19 crore in March 2025, leading to a total operating income that also fell sharply. Expenditures were notably high in March 2022 but have since decreased, resulting in a slight operating profit in March 2025. Despite this, the company has struggled to maintain profitability, with profit after tax only reaching 0.01 crore in March 2025. The balance sheet shows a rise in total liabilities and assets, indicating some growth, while cash flow from operating activities turned positive in March 2025, marking a potential turning point for the company.